Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CCR3 | P51677 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241082 | 0.88 | SLC6A2 (0.71) | SLC6A2SLC6A4TSHRCCR3ALDH1A1 | |
| SCHEMBL6427944 | 0.84 | MEN1 (0.61) | SLC6A2SLC6A4TSHRCCR3ALDH1A1 | |
| SCHEMBL3540368 | 0.81 | SLC6A2 (0.63) | SLC6A2SLC6A4TSHRCCR3ALDH1A1 | |
| SCHEMBL13673491 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4TSHRCCR3ALDH1A1 | |
| SCHEMBL2952169 | 0.80 | MEN1 (0.65) | SLC6A2SLC6A4ALDH1A1MAPT | |
| SCHEMBL2776292 | 0.80 | SLC6A2 (0.55) | SLC6A2SLC6A4TSHRCCR3LMNA | |
| SCHEMBL7850831 | 0.80 | HRH3 (0.57) | SLC6A2SLC6A4TSHRCCR3CARM1 | |
| SCHEMBL5889215 | 0.80 | ALDH1A1 (0.58) | SLC6A2SLC6A4TSHRALDH1A1LMNA | |
| SCHEMBL3323867 | 0.78 | SMN1; SMN2 (0.54) | SLC6A2SLC6A4TSHRCCR3ATM | |
| SCHEMBL6428994 | 0.78 | GAA (0.70) | SLC6A2SLC6A4ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| EP-2268612-B1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| CN-102036953-A | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | SLC6A2 1417/4885SLC6A4 1223/4885TSHR 2274/4885 |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | MMP11, MMP10, MMP9 | SLC6A2 1417/4885SLC6A4 1223/4885TSHR 2274/4885 |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | SLC6A2 1574/4885SLC6A4 1281/4885TSHR 2169/4885 |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | SLC6A2 1574/4885SLC6A4 1281/4885TSHR 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.